Gian Luigi Gessa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gian Luigi Gessa has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
G Colombo
5 shared publicationsC Lobina
4 shared publicationsGiancarlo Colombo
Neuroscience Institute, National Research Council of Italy, Section of Cagliari, S.S. 554 km. 4,500, I-09042 Monserrato (CA), Italy
4 shared publications- Marco Diana
University of Sassari
4 shared publications - Mauro A.M Carai
Neuroscienze S.c.a r.l., Via Palabanda 9, I-09123 Cagliari, Italy
4 shared publications - Miriam Melis
Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy
4 shared publications
Latest Publications
- Open Access
- 26 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 838
Sex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain
As sex-gender differences have been described in the responses of patients to certain medications, we hypothesized that the responses to medications recommended for neuropathic pain may differ between men and women. We conducted a literature review to identify articles reporting potential sex-gender differences in the efficacy and safety of these medications. Only a limited number of studies investigated potential sex-gender differences. Our results show that women seem to achieve higher blood concentrations than men during treatment with amitriptyline, nortriptyline, duloxetine, venlafaxine, and pregabalin. Compared to men, higher rates of women develop side effects during treatment with gabapentin, lidocaine, and tramadol. Globally, the sex-gender differences would suggest initially administering smaller doses of these medications to women with neuropathic pain compared to those administered to men. However, most of these differences have been revealed by studies focused on the treatment of other diseases (e.g., depression). Studies focused on neuropathic pain have overlooked potential sex-gender differences in patient responses to medications. Despite the fact that up to 60% of patients with neuropathic pain fail to achieve an adequate response to medications, the potential role of sex-gender differences in the efficacy and safety of pharmacotherapy has not adequately been investigated. Targeted studies should be implemented to facilitate personalized treatments for neuropathic pain.
- 26 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 838
Open AccessSex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain
As sex-gender differences have been described in the responses of patients to certain medications, we hypothesized that the responses to medications recommended for neuropathic pain may differ between men and women. We conducted a literature review to identify articles reporting potential sex-gender differences in the efficacy and safety of these medications. Only a limited number of studies investigated potential sex-gender differences. Our results show that women seem to achieve higher blood concentrations than men during treatment with amitriptyline, nortriptyline, duloxetine, venlafaxine, and pregabalin. Compared to men, higher rates of women develop side effects during treatment with gabapentin, lidocaine, and tramadol. Globally, the sex-gender differences would suggest initially administering smaller doses of these medications to women with neuropathic pain compared to those administered to men. However, most of these differences have been revealed by studies focused on the treatment of other diseases (e.g., depression). Studies focused on neuropathic pain have overlooked potential sex-gender differences in patient responses to medications. Despite the fact that up to 60% of patients with neuropathic pain fail to achieve an adequate response to medications, the potential role of sex-gender differences in the efficacy and safety of pharmacotherapy has not adequately been investigated. Targeted studies should be implemented to facilitate personalized treatments for neuropathic pain.
- Open Access
- 13 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4688
Gender Differences among Sardinians with Alcohol Use Disorder
Sardinia is an Italian island in the Mediterranean characterized by secular isolation and the singular genetic characteristics of its inhabitants. Findings obtained in populations with diverse genetic make-up and cultural background indicate gender differences and/or similarities in drinking characteristics of patients with alcohol use disorder (AUD). Knowledge of these characteristics in AUD patients is useful to improve access to treatments. This paper investigated the drinking characteristics of 66 female and 282 male outpatients with AUD, born from 1937 to 1991, living in Sardinia, and compared their characteristics with those of AUD patients living in other countries. Most Sardinian patients were men, approximately 3 years younger than women; women consumed lower amounts of alcohol than men but did not differ from men in the severity of AUD. Men were more often single than women, while a higher proportion of women reported that their mother or spouse was affected by AUD. Anxiety and depression were more prevalent among women while a higher proportion of men were affected by substance use disorders. Women were older than men at the age of first drink, regular drinking, and onset of AUD, and progressed faster than men from regular use to AUD onset. Women did not differ from men in age at first request for care, and in the lapse from AUD onset to first request for care. Women and men waited for more than 8 and 9 years, respectively, before receiving medical treatment. Gender differences progressively decreased among younger patients. Although the scarce number of women in some cohorts limits the strength of these findings, drinking characteristics of Sardinian patients did not vary significantly from those of AUD patients living in other countries. These results suggest that the number of Sardinian women with AUD is increasing and services for treatment of AUD should (a) consider women’s specific needs, and (b) realize effective policies to reduce latency prior to accessing medical treatment for both men and women with AUD.
- 13 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4688
Open AccessGender Differences among Sardinians with Alcohol Use Disorder
Sardinia is an Italian island in the Mediterranean characterized by secular isolation and the singular genetic characteristics of its inhabitants. Findings obtained in populations with diverse genetic make-up and cultural background indicate gender differences and/or similarities in drinking characteristics of patients with alcohol use disorder (AUD). Knowledge of these characteristics in AUD patients is useful to improve access to treatments. This paper investigated the drinking characteristics of 66 female and 282 male outpatients with AUD, born from 1937 to 1991, living in Sardinia, and compared their characteristics with those of AUD patients living in other countries. Most Sardinian patients were men, approximately 3 years younger than women; women consumed lower amounts of alcohol than men but did not differ from men in the severity of AUD. Men were more often single than women, while a higher proportion of women reported that their mother or spouse was affected by AUD. Anxiety and depression were more prevalent among women while a higher proportion of men were affected by substance use disorders. Women were older than men at the age of first drink, regular drinking, and onset of AUD, and progressed faster than men from regular use to AUD onset. Women did not differ from men in age at first request for care, and in the lapse from AUD onset to first request for care. Women and men waited for more than 8 and 9 years, respectively, before receiving medical treatment. Gender differences progressively decreased among younger patients. Although the scarce number of women in some cohorts limits the strength of these findings, drinking characteristics of Sardinian patients did not vary significantly from those of AUD patients living in other countries. These results suggest that the number of Sardinian women with AUD is increasing and services for treatment of AUD should (a) consider women’s specific needs, and (b) realize effective policies to reduce latency prior to accessing medical treatment for both men and women with AUD.
- Open Access
- 18 June 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6) , 1913
Delineating the Psychic Structure of Substance Use and Addictions, from Neurobiology to Clinical Implications: Ten Years Later
The diagnosis of substance use disorder is currently based on the presence of specifically identified behavioral symptoms. In addition, other psychiatric signs and symptoms accompany addictive behavior, contributing to the full picture of patients’ psychopathologic profile. Historically, such symptoms were confined within the framework of “comorbidity”, as comorbid psychiatric disorders or personality traits. However, an alternative unitary view of the psychopathology of addiction, inclusive of related psychiatric symptoms, has been claimed, with the support of epidemiological, neurobiological, and neuropsychological evidence. In the present article, we highlight the research advancements that strengthen this unified perspective. We then give an account of our group’s definition of a specific SCL-90-based construct of the psychopathology of addiction. Lastly, we discuss the benefits that can be expected to be acquired in the evaluation and treatment of patients with a longitudinal approach including psychological/psychiatric predisposing features, addictive behavior, and psychiatric manifestations.
- 18 June 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6) , 1913
Open AccessDelineating the Psychic Structure of Substance Use and Addictions, from Neurobiology to Clinical Implications: Ten Years Later
The diagnosis of substance use disorder is currently based on the presence of specifically identified behavioral symptoms. In addition, other psychiatric signs and symptoms accompany addictive behavior, contributing to the full picture of patients’ psychopathologic profile. Historically, such symptoms were confined within the framework of “comorbidity”, as comorbid psychiatric disorders or personality traits. However, an alternative unitary view of the psychopathology of addiction, inclusive of related psychiatric symptoms, has been claimed, with the support of epidemiological, neurobiological, and neuropsychological evidence. In the present article, we highlight the research advancements that strengthen this unified perspective. We then give an account of our group’s definition of a specific SCL-90-based construct of the psychopathology of addiction. Lastly, we discuss the benefits that can be expected to be acquired in the evaluation and treatment of patients with a longitudinal approach including psychological/psychiatric predisposing features, addictive behavior, and psychiatric manifestations.
- 22 May 2020
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 55 (4) , 367-373
Differential Effects of Saikosaponins A, B2, B4, C and D on Alcohol and Chocolate Self-Administration in Rats
Aims Treatment with saikosaponin A (SSA)—an ingredient of the medicinal herb, Bupleurum falcatum—has been reported to suppress several addictive-like behaviors, including morphine, cocaine, alcohol and chocolate self-administration in male rats. The aim of this investigation was to investigate whether saikosaponins of B. falcatum other than SSA affect alcohol and chocolate self-administration in rats. Methods Ovariectomized female Sardinian alcohol-preferring (sP) and Wistar rats were trained to self-administer alcohol (15%, v/v) and a chocolate solution [5% (w/v) Nesquik® in water], respectively, under fixed ratio schedules of reinforcement. The following saikosaponins were compared to SSA: saikosaponin D (SSD; epimer of SSA), saikosaponin C (SSC), saikosaponin B2 (SSB2) and saikosaponin B4 (SSB4). All saikosaponins were tested acutely at the doses of 0, 0.25, 0.5 and 1 mg/kg (i.p.). Results Treatment with SSA and SSD resulted in highly similar, marked reductions in alcohol self-administration; SSC failed to alter lever-responding for alcohol, while SSB2 and SSB4 produced intermediate reductions. Only SSA and SSD reduced chocolate self-administration, with SSC, SSB2 and SSB4 being ineffective. Conclusions The wide spectrum of efficacy of saikosaponins in reducing alcohol and chocolate self-administration suggests that even relatively small structural differences are sufficient to produce remarkable changes in their in vivo pharmacological profile. Together, these results confirm that roots of B. falcatum may be an interesting source of compounds with anti-addictive potential.
- 22 May 2020
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 55 (4) , 367-373
Differential Effects of Saikosaponins A, B2, B4, C and D on Alcohol and Chocolate Self-Administration in Rats
Aims Treatment with saikosaponin A (SSA)—an ingredient of the medicinal herb, Bupleurum falcatum—has been reported to suppress several addictive-like behaviors, including morphine, cocaine, alcohol and chocolate self-administration in male rats. The aim of this investigation was to investigate whether saikosaponins of B. falcatum other than SSA affect alcohol and chocolate self-administration in rats. Methods Ovariectomized female Sardinian alcohol-preferring (sP) and Wistar rats were trained to self-administer alcohol (15%, v/v) and a chocolate solution [5% (w/v) Nesquik® in water], respectively, under fixed ratio schedules of reinforcement. The following saikosaponins were compared to SSA: saikosaponin D (SSD; epimer of SSA), saikosaponin C (SSC), saikosaponin B2 (SSB2) and saikosaponin B4 (SSB4). All saikosaponins were tested acutely at the doses of 0, 0.25, 0.5 and 1 mg/kg (i.p.). Results Treatment with SSA and SSD resulted in highly similar, marked reductions in alcohol self-administration; SSC failed to alter lever-responding for alcohol, while SSB2 and SSB4 produced intermediate reductions. Only SSA and SSD reduced chocolate self-administration, with SSC, SSB2 and SSB4 being ineffective. Conclusions The wide spectrum of efficacy of saikosaponins in reducing alcohol and chocolate self-administration suggests that even relatively small structural differences are sufficient to produce remarkable changes in their in vivo pharmacological profile. Together, these results confirm that roots of B. falcatum may be an interesting source of compounds with anti-addictive potential.
- 1 October 2019
- Published by Elsevier in Pharmacological Research
- Vol. 148, 104447
Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis
- 1 October 2019
- Published by Elsevier in Pharmacological Research
- Vol. 148, 104447
Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis
- 8 February 2016
- Published by Elsevier in Brain Research
- Vol. 1645, 55-57
The long pursued Holy Grail of the true “alcoholic” rat
- 8 February 2016
- Published by Elsevier in Brain Research
- Vol. 1645, 55-57
The long pursued Holy Grail of the true “alcoholic” rat
- Open Access
- 12 August 2013
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 48 (suppl 1) , i34-i35
O1 * FREE ORAL COMMUNICATIONS 1: BASIC NEUROBIOLOGICAL MECHANISMS OF ALCOHOL ADDICTION
MicroRNAs are master regulators of gene expression. They are particularly important in brain function. Previously, we observed that short exposure to 20mM ethanol upregulated miR-9 in primary rodent neuronal cultures or brain organotypic slices. These observations prompted us to perform more detailed temporal characteristics and dose-dependence of miR-9 response to ethanol using a regimen of ethanol exposures and withdrawals. We used two physiologically-relevent ethanol concentrations 20 mM and 50 mM. Exposure and/or withdrawal ranged from 15 minutes to 24 hours. We used postnatal day 5 striatal medium spiny neurons harvested from C57BL/6 mice. Total RNA and small RNA fraction (<200 nt) were isolated and treated with DNase. Concentrations of mature mmu-miR-9, miR-9* and miR-9 precursors: pre-miR-9-1, -9-2, and -9-3 were determined by qRT-PCR. Preliminary results indicate that exposure to 20 mM but not 50 mM ethanol for 15 min caused an almost 2-fold increase in miR-9 expression. Interestingly, the expression of pre-mir-9-1 was also increased in response to ethanol. We are currently testing ethanol effect on expression of pre-miR-9-2 and -9-3 precursors. We are also trying to understand interplay between genetic (SNPs) and epigenetic (DNA methylation) mechanisms on regulation of expression of mir-9 genes by ethanol. We performed sequencing of promoters of mir-9 genes using human samples and observed presence of several SNPs in these regions. Some of these SNPs could alter binding of transcription factors and/or promoter methylation. Together, these results can provide new understanding of development of alcohol addiction.
- 12 August 2013
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 48 (suppl 1) , i34-i35
Open AccessO1 * FREE ORAL COMMUNICATIONS 1: BASIC NEUROBIOLOGICAL MECHANISMS OF ALCOHOL ADDICTION
MicroRNAs are master regulators of gene expression. They are particularly important in brain function. Previously, we observed that short exposure to 20mM ethanol upregulated miR-9 in primary rodent neuronal cultures or brain organotypic slices. These observations prompted us to perform more detailed temporal characteristics and dose-dependence of miR-9 response to ethanol using a regimen of ethanol exposures and withdrawals. We used two physiologically-relevent ethanol concentrations 20 mM and 50 mM. Exposure and/or withdrawal ranged from 15 minutes to 24 hours. We used postnatal day 5 striatal medium spiny neurons harvested from C57BL/6 mice. Total RNA and small RNA fraction (<200 nt) were isolated and treated with DNase. Concentrations of mature mmu-miR-9, miR-9* and miR-9 precursors: pre-miR-9-1, -9-2, and -9-3 were determined by qRT-PCR. Preliminary results indicate that exposure to 20 mM but not 50 mM ethanol for 15 min caused an almost 2-fold increase in miR-9 expression. Interestingly, the expression of pre-mir-9-1 was also increased in response to ethanol. We are currently testing ethanol effect on expression of pre-miR-9-2 and -9-3 precursors. We are also trying to understand interplay between genetic (SNPs) and epigenetic (DNA methylation) mechanisms on regulation of expression of mir-9 genes by ethanol. We performed sequencing of promoters of mir-9 genes using human samples and observed presence of several SNPs in these regions. Some of these SNPs could alter binding of transcription factors and/or promoter methylation. Together, these results can provide new understanding of development of alcohol addiction.
- 8 April 2013
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 110 (8) , 1524-1533
The dopamine β-hydroxylase inhibitor, nepicastat, suppresses chocolate self-administration and reinstatement of chocolate seeking in rats
Craving for chocolate is a common phenomenon, which may evolve to an addictive-like behaviour and contribute to obesity. Nepicastat is a selective dopamine β-hydroxylase (DBH) inhibitor that suppresses cocaine-primed reinstatement of cocaine seeking in rats. We verified whether nepicastat was able to modify the reinforcing and motivational properties of a chocolate solution and to prevent the reinstatement of chocolate seeking in rats. Nepicastat (25, 50 and 100 mg/kg, intraperitoneal) produced a dose-related inhibition of operant self-administration of the chocolate solution in rats under fixed-ratio 10 (FR10) and progressive-ratio schedules of reinforcement, measures of the reinforcing and motivational properties of the chocolate solution, respectively. The effect of nepicastat on the reinstatement of chocolate seeking was studied in rats in which lever-responding had been extinguished by removing the chocolate solution for approximately 8 d. Nepicastat dose-dependently suppressed the reinstatement of lever-responding triggered by a ‘priming’ of the chocolate solution together with cues previously associated with the availability of the reward. In a separate group of food-restricted rats trained to lever-respond for regular food pellets, nepicastat reduced FR10 lever-responding with the same potency as for the chocolate solution. Spontaneous locomotor activity was not modified by nepicastat doses that reduced self-administration of the chocolate solution and regular food pellets and suppressed the reinstatement of chocolate seeking. The results indicate that nepicastat reduces motivation to food consumption sustained by appetite or palatability. Moreover, the results suggest that DBH inhibitors may be a new class of pharmacological agents potentially useful in the prevention of relapse to food seeking in human dieters.
- 8 April 2013
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 110 (8) , 1524-1533
The dopamine β-hydroxylase inhibitor, nepicastat, suppresses chocolate self-administration and reinstatement of chocolate seeking in rats
Craving for chocolate is a common phenomenon, which may evolve to an addictive-like behaviour and contribute to obesity. Nepicastat is a selective dopamine β-hydroxylase (DBH) inhibitor that suppresses cocaine-primed reinstatement of cocaine seeking in rats. We verified whether nepicastat was able to modify the reinforcing and motivational properties of a chocolate solution and to prevent the reinstatement of chocolate seeking in rats. Nepicastat (25, 50 and 100 mg/kg, intraperitoneal) produced a dose-related inhibition of operant self-administration of the chocolate solution in rats under fixed-ratio 10 (FR10) and progressive-ratio schedules of reinforcement, measures of the reinforcing and motivational properties of the chocolate solution, respectively. The effect of nepicastat on the reinstatement of chocolate seeking was studied in rats in which lever-responding had been extinguished by removing the chocolate solution for approximately 8 d. Nepicastat dose-dependently suppressed the reinstatement of lever-responding triggered by a ‘priming’ of the chocolate solution together with cues previously associated with the availability of the reward. In a separate group of food-restricted rats trained to lever-respond for regular food pellets, nepicastat reduced FR10 lever-responding with the same potency as for the chocolate solution. Spontaneous locomotor activity was not modified by nepicastat doses that reduced self-administration of the chocolate solution and regular food pellets and suppressed the reinstatement of chocolate seeking. The results indicate that nepicastat reduces motivation to food consumption sustained by appetite or palatability. Moreover, the results suggest that DBH inhibitors may be a new class of pharmacological agents potentially useful in the prevention of relapse to food seeking in human dieters.
- Open Access
- 2 May 2005
- Published by Springer Nature in BMC Neuroscience
- Vol. 6 (1) , 31
Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus
Background: Previous studies by our group suggest that extracellular dopamine (DA) and noradrenaline (NA) may be co-released from noradrenergic nerve terminals in the cerebral cortex. We recently demonstrated that the concomitant release of DA and NA could be elicited in the cerebral cortex by electrical stimulation of the locus coeruleus (LC). This study analyses the effect of both single train and repeated electrical stimulation of LC on NA and DA release in the medial prefrontal cortex (mPFC), occipital cortex (Occ), and caudate nucleus. To rule out possible stressful effects of electrical stimulation, experiments were performed on chloral hydrate anaesthetised rats. Results: Twenty min electrical stimulation of the LC, with burst type pattern of pulses, increased NA and DA both in the mPFC and in the Occ. NA in both cortices and DA in the mPFC returned to baseline within 20 min after the end of the stimulation period, while DA in the Occ reached a maximum increase during 20 min post-stimulation and remained higher than baseline values at 220 min post-stimulation. Local perfusion with tetrodotoxin (TTX, 10 μM) markedly reduced baseline NA and DA in the mPFC and Occ and totally suppressed the effect of electrical stimulation in both areas. A sequence of five 20 min stimulations at 20 min intervals were delivered to the LC. Each stimulus increased NA to the same extent and duration as the first stimulus, whereas DA remained elevated at the time next stimulus was delivered, so that baseline DA progressively increased in the mPFC and Occ to reach about 130 and 200% the initial level, respectively. In the presence of the NA transport (NAT) blocker desipramine (DMI, 100 μM), multiple LC stimulation still increased extracellular NA and DA levels. Electrical stimulation of the LC increased NA levels in the homolateral caudate nucleus, but failed to modify DA level. Conclusion: The results confirm and extend that LC stimulation induces a concomitant release of DA and NA in the mPFC and Occ. The different time-course of LC-induced elevation of DA and NA suggests that their co-release may be differentially controlled.
- 2 May 2005
- Published by Springer Nature in BMC Neuroscience
- Vol. 6 (1) , 31
Open AccessCo-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus
Background: Previous studies by our group suggest that extracellular dopamine (DA) and noradrenaline (NA) may be co-released from noradrenergic nerve terminals in the cerebral cortex. We recently demonstrated that the concomitant release of DA and NA could be elicited in the cerebral cortex by electrical stimulation of the locus coeruleus (LC). This study analyses the effect of both single train and repeated electrical stimulation of LC on NA and DA release in the medial prefrontal cortex (mPFC), occipital cortex (Occ), and caudate nucleus. To rule out possible stressful effects of electrical stimulation, experiments were performed on chloral hydrate anaesthetised rats. Results: Twenty min electrical stimulation of the LC, with burst type pattern of pulses, increased NA and DA both in the mPFC and in the Occ. NA in both cortices and DA in the mPFC returned to baseline within 20 min after the end of the stimulation period, while DA in the Occ reached a maximum increase during 20 min post-stimulation and remained higher than baseline values at 220 min post-stimulation. Local perfusion with tetrodotoxin (TTX, 10 μM) markedly reduced baseline NA and DA in the mPFC and Occ and totally suppressed the effect of electrical stimulation in both areas. A sequence of five 20 min stimulations at 20 min intervals were delivered to the LC. Each stimulus increased NA to the same extent and duration as the first stimulus, whereas DA remained elevated at the time next stimulus was delivered, so that baseline DA progressively increased in the mPFC and Occ to reach about 130 and 200% the initial level, respectively. In the presence of the NA transport (NAT) blocker desipramine (DMI, 100 μM), multiple LC stimulation still increased extracellular NA and DA levels. Electrical stimulation of the LC increased NA levels in the homolateral caudate nucleus, but failed to modify DA level. Conclusion: The results confirm and extend that LC stimulation induces a concomitant release of DA and NA in the mPFC and Occ. The different time-course of LC-induced elevation of DA and NA suggests that their co-release may be differentially controlled.
- Open Access
- 6 December 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 40 (1) , 46-53
SUPPRESSING EFFECT OF THE CANNABINOID CB1 RECEPTOR ANTAGONIST, SR147778, ON ALCOHOL INTAKE AND MOTIVATIONAL PROPERTIES OF ALCOHOL IN ALCOHOL-PREFERRING sP RATS
Aims: The present study investigated the effect of the newly synthesized cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and the motivational properties of alcohol in selectively bred Sardinian alcohol-preferring (sP) rats. Methods and Results: In Experiment 1, the repeated administration of SR147778 (0.3–3 mg/kg twice daily, i.p.) specifically suppressed the acquisition of alcohol drinking behaviour in alcohol-naive rats exposed to the two-bottle ‘alcohol vs water’ choice regimen for 24 h/day. In Experiment 2, an acute administration of SR147778 (2.5–10 mg/kg, i.p.) specifically reduced alcohol intake in alcohol-experienced rats that were given alcohol and water under the two-bottle choice regimen in daily sessions of 4 h. In Experiment 3, an acute administration of SR147778 (0.3–3 mg/kg, i.p.) suppressed the ‘alcohol deprivation effect’, i.e. the extra-intake of alcohol occurring after a period of alcohol abstinence. In Experiment 4, an acute administration of SR147778 (0.3–3 mg/kg, i.p.) specifically suppressed the extinction responding for alcohol, i.e. the maximal number of lever responses reached in the absence of alcohol in rats trained to lever-press for alcohol (measure of the motivational properties of alcohol). In Experiment 5, the combination of 3 mg/kg of SR147778 (i.p.) and 0.5 g/kg of alcohol (i.p.), a dose comparable with those usually consumed by sP rats in each drinking binge, failed to induce any conditioned taste aversion. Conclusion: Taken together, these results extend to SR147778 the anti-alcohol profile of the prototype cannabinoid CB1 receptor antagonist, rimonabant (SR141716), and strengthen the hypothesis that the cannabinoid CB1 receptor is part of the neural substrate mediating alcohol intake and the motivational properties of alcohol.
- 6 December 2004
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 40 (1) , 46-53
Open AccessSUPPRESSING EFFECT OF THE CANNABINOID CB1 RECEPTOR ANTAGONIST, SR147778, ON ALCOHOL INTAKE AND MOTIVATIONAL PROPERTIES OF ALCOHOL IN ALCOHOL-PREFERRING sP RATS
Aims: The present study investigated the effect of the newly synthesized cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and the motivational properties of alcohol in selectively bred Sardinian alcohol-preferring (sP) rats. Methods and Results: In Experiment 1, the repeated administration of SR147778 (0.3–3 mg/kg twice daily, i.p.) specifically suppressed the acquisition of alcohol drinking behaviour in alcohol-naive rats exposed to the two-bottle ‘alcohol vs water’ choice regimen for 24 h/day. In Experiment 2, an acute administration of SR147778 (2.5–10 mg/kg, i.p.) specifically reduced alcohol intake in alcohol-experienced rats that were given alcohol and water under the two-bottle choice regimen in daily sessions of 4 h. In Experiment 3, an acute administration of SR147778 (0.3–3 mg/kg, i.p.) suppressed the ‘alcohol deprivation effect’, i.e. the extra-intake of alcohol occurring after a period of alcohol abstinence. In Experiment 4, an acute administration of SR147778 (0.3–3 mg/kg, i.p.) specifically suppressed the extinction responding for alcohol, i.e. the maximal number of lever responses reached in the absence of alcohol in rats trained to lever-press for alcohol (measure of the motivational properties of alcohol). In Experiment 5, the combination of 3 mg/kg of SR147778 (i.p.) and 0.5 g/kg of alcohol (i.p.), a dose comparable with those usually consumed by sP rats in each drinking binge, failed to induce any conditioned taste aversion. Conclusion: Taken together, these results extend to SR147778 the anti-alcohol profile of the prototype cannabinoid CB1 receptor antagonist, rimonabant (SR141716), and strengthen the hypothesis that the cannabinoid CB1 receptor is part of the neural substrate mediating alcohol intake and the motivational properties of alcohol.